JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

Benzinga Newsdesk www.benzinga.com Negative 89.5%

Neg 89.5% Neu 0% Pos 0%

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.